PROLOGUE评分外部验证:预测成人心脏骤停后神经功能结局的前瞻性队列研究
本研究为前瞻性队列研究,连续纳入2012年10月至2022年7月入住瑞士某三级教学医院ICU的成人心脏骤停患者,旨在外部验证PROLOGUE评分对出院时不良神经结局(CPC 3-5分含死亡)的预测效能,并与OHCA和CAHP评分比较。共纳入687例,321例(46.7%)存活且神经结局良好,68例(9.9%)存活但神经结局不良,298例(43.4%)死亡。PROLOGUE评分AUROC为0.83(95%CI 0.80-0.86),校准良好;OHCA和CAHP评分AUROC分别为0.83和0.84,三者差异无统计学意义(p=0.495)。亚组分析中,PROLOGUE评分在院外和院内心脏骤停患者中表现相当,而OHCA和CAHP评分在院外心脏骤停患者中显著更优。结论认为PROLOGUE评分在本队列中具有良好的早期预后预测准确性,或可支持ICU早期治疗目标讨论。
要点
- PROLOGUE评分预测成人心脏骤停后出院时不良神经结局(CPC 3-5分)的AUROC为0.83(95%CI 0.80-0.86),校准良好。
- OHCA评分AUROC为0.83,CAHP评分AUROC为0.84,与PROLOGUE评分差异无统计学意义(p=0.495)。
- 亚组分析中PROLOGUE评分在院外和院内心脏骤停患者中表现相当,OHCA和CAHP评分在院外心脏骤停患者中显著更优。
- 687例患者中321例(46.7%)存活且神经结局良好,68例(9.9%)存活但神经结局不良,298例(43.4%)死亡。
- 作者认为PROLOGUE评分或可支持ICU早期治疗目标讨论。
适用人群与场景
- 连续纳入2012年10月至2022年7月入住瑞士某三级教学医院ICU的成人心脏骤停患者。
诊断标准与关键阈值
- 主要终点为出院时不良神经结局,定义为CPC评分3至5分(包括死亡)。
研究设计与关键结果
- 研究类型为前瞻性队列研究,纳入687例成人心脏骤停患者,来自瑞士某三级教学医院ICU。
- 主要终点出院时不良神经结局(CPC 3-5分含死亡):PROLOGUE评分AUROC为0.83(95%CI 0.80-0.86),校准良好。
- OHCA评分AUROC为0.83,CAHP评分AUROC为0.84,三种评分差异无统计学意义(p=0.495)。
- 687例中321例(46.7%)存活且神经结局良好,68例(9.9%)存活但神经结局不良,298例(43.4%)死亡。
- 亚组分析:PROLOGUE评分在院外和院内心脏骤停患者中表现相当;OHCA和CAHP评分在院外心脏骤停患者中显著更优。
证据类型、等级与局限
- 证据类型:前瞻性队列研究(外部验证)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为PROLOGUE评分可能支持ICU内早期治疗目标讨论。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The PROLOGUE score (PROgnostication using LOGistic regression model for Unselected adult cardiac arrest patients in the Early stages) is a novel prognostic model for the prediction of neurological outcome after cardiac arrest, which showed exceptional performance in the internal validation. The aim of this study is to validate the PROLOGUE score in an independent cohort of unselected adult cardiac arrest patients and to compare it to the thoroughly validated Out-of-Hospital Cardiac Arrest (OHCA) and Cardiac Arrest Hospital Prognosis (CAHP) scores.
METHODS: This study included consecutive adult cardiac arrest patients admitted to the intensive care unit (ICU) of a Swiss tertiary teaching hospital between October 2012 and July 2022. The primary endpoint was poor neurological outcome at hospital discharge, defined as a Cerebral Performance Category (CPC) score of 3 to 5 including death.
RESULTS: Of 687 patients included in the analysis, 321 (46.7%) survived to hospital discharge with good neurological outcome, 68 (9.9%) survived with poor neurological outcome and 298 (43.4%) died. The PROLOGUE score showed an area under the receiver operating characteristic curve (AUROC) of 0.83 (95% CI 0.80 to 0.86) and good calibration for the prediction of the primary outcome. The OHCA and CAHP score showed similar performance (AUROC 0.83 and 0.84 respectively), the differences between the three scores were not significant (p = 0.495). In a subgroup analysis, the PROLOGUE score performed equally in out-of-hospital and in-hospital cardiac arrest patients whereas the OHCA and CAHP score performed significantly better in OHCA patients.
CONCLUSION: The PROLOGUE score showed good prognostic accuracy for the early prediction of neurological outcome in adult cardiac arrest survivors in our cohort and might support early goals-of-care discussions in the ICU. Trial registration Not applicable.
参考来源
- Blatter R, Gökduman B, Amacher SA, et al. External validation of the PROLOGUE score to predict neurological outcome in adult patients after cardiac arrest: a prospective cohort study. Scand J Trauma Resusc Emerg Med. 2023. PMID: 37016393. doi:10.1186/s13049-023-01081-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。